Monday 18 August 2025

Pharma & Biotech Start-up & Scale-up News

Featured

VenatoRx Pharma
VenatoRx Pharmaceuticals is a private, clinical-stage pharmaceutical company dedicated to the discovery and development of new medicines to treat drug-resistant infections.
Biotechnology
Biocytogen inks antibody deal with BeOne, expanding strategic ties
10 July 2025
article
IDEAYA exercises option for license on Biocytogen’s IDE034
11 November 2024

Latest Ones To Watch News

Biotechnology
Anocca secures $46 million to advance KRAS-targeted T-cell therapy
18 August 2025
Pharmaceutical
FDA review timeline extended for NUZ-001 IND clinical hold
18 August 2025
Pharmaceutical
Basilea inks antibiotic deal with Venatorx
15 August 2025
More ones to watch news >
Reset all filters
Refine Search
Nanoscope Therapeutics
Nanoscope Therapeutics
ARTBIO
ARTBIO
Ascendis Pharma
Memo Therapeutics
Avidity Biosciences
Apnimed
Neuraxpharm
OncoZenge
Nanobiotix
Summit
MaaT Pharma
Nuvalent
UroGen Pharma
Tubulis
Neurocrine Biosciences
Axsome Therapeutics
Cidara Therapeutics
Halda Therapeutics
Opthea
Soleno Therapeutics


Today's issue

Anocca secures $46 million to advance KRAS-targeted T-cell therapy
Biotechnology
Anocca secures $46 million to advance KRAS-targeted T-cell therapy
18 August 2025
Pharmaceutical
Nathan Pennell joins BMS exec team
18 August 2025
Pharmaceutical
EC approves Ogsiveo, first treatment for desmoid tumors
18 August 2025
Biotechnology
Boehringer and Palatin team up on retinal diseases research
18 August 2025
Biotechnology
Bladder cancer market to reach $16 billion in 8MM in 2033
18 August 2025
Pharmaceutical
Eisai debuts anti-insomnia drug Dayvigo in China
18 August 2025
Pharmaceutical
LEO Pharma delivers 7% revenue growth in 1st-half 2025
18 August 2025

Company Spotlight

VenatoRx Pharmaceuticals is a private, clinical-stage pharmaceutical company dedicated to the discovery and development of new medicines to treat drug-resistant infections.




Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze